{"id":41420,"date":"2022-03-03T17:35:25","date_gmt":"2022-03-03T17:35:25","guid":{"rendered":"https:\/\/elpais.com\/ciencia\/2022-03-03\/un-antiinflamatorio-de-unos-300-euros-reduce-un-20-las-muertes-por-covid-de-los-enfermos-graves.html"},"modified":"2022-03-03T17:35:25","modified_gmt":"2022-03-03T17:35:25","slug":"un-antiinflamatorio-de-unos-300-euros-reduce-un-20-las-muertes-por-covid-de-los-enfermos-graves","status":"publish","type":"post","link":"http:\/\/forocilac.org\/en\/un-antiinflamatorio-de-unos-300-euros-reduce-un-20-las-muertes-por-covid-de-los-enfermos-graves\/","title":{"rendered":"An anti-inflammatory costing about 300 euros reduces deaths from covid among seriously ill people by 20%"},"content":{"rendered":"<p>La humanidad ya no est\u00e1 indefensa ante el nuevo coronavirus. La letalidad de la covid se ha reducido 20 veces desde hace un a\u00f1o, <a href=\"https:\/\/www.youtube.com\/watch?v=1HkwNPQ2l8Q\" >hasta llegar al 0,15%<\/a> de la actual ola en Espa\u00f1a, gracias a la vacunaci\u00f3n masiva, pero tambi\u00e9n al perfeccionamiento de los tratamientos contra el virus. Y el arsenal aumenta. Un ensayo cl\u00ednico con 8.000 pacientes en Reino Unido ha demostrado que un antiinflamatorio, el baricitinib, reduce un 13% la mortalidad de los enfermos hospitalizados con covid grave. Si se incluyen los datos de otros 4.000 pacientes en ensayos previos, la reducci\u00f3n de la mortalidad alcanza el 20%, seg\u00fan <a href=\"https:\/\/www.recoverytrial.net\/news\/baricitinib\">los resultados preliminares<\/a> publicados este jueves.<\/p>\n<p><a href=\"https:\/\/elpais.com\/ciencia\/2022-03-03\/un-antiinflamatorio-de-unos-300-euros-reduce-un-20-las-muertes-por-covid-de-los-enfermos-graves.html\" >Keep reading<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Baricitinib, commonly used against rheumatoid arthritis, joins a medical arsenal that has possibly already saved millions of lives<\/p>","protected":false},"author":25,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[123],"tags":[],"class_list":{"0":"post-41420","1":"post","2":"type-post","3":"status-publish","4":"format-standard","6":"category-portal"},"aioseo_notices":[],"_links":{"self":[{"href":"http:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/posts\/41420","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/users\/25"}],"replies":[{"embeddable":true,"href":"http:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/comments?post=41420"}],"version-history":[{"count":1,"href":"http:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/posts\/41420\/revisions"}],"predecessor-version":[{"id":41421,"href":"http:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/posts\/41420\/revisions\/41421"}],"wp:attachment":[{"href":"http:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/media?parent=41420"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/categories?post=41420"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/tags?post=41420"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}